Emily C Ayers, Shaoying Li, L Jeffrey Medeiros, David A Bond, Kami J Maddocks, Pallawi Torka, Angel Mier Hicks, Madeira Curry, Nina D Wagner-Johnston, Reem Karmali, Amir Behdad, Bita Fakhri, Brad S Kahl, Michael C Churnetski, Jonathon B Cohen, Nishitha M Reddy, Dipenkumar Modi, Radhakrishnan Ramchandren, Christina Howlett, Lori A Leslie, Samuel Cytryn, Catherine S Diefenbach, Rawan Faramand, Julio C Chavez, Adam J Olszewski, Yang Liu, Stefan K Barta, Dhruvika Mukhija, Brian T Hill, Helen Ma, Jennifer E Amengual, Sunita Nathan, Sarit E Assouline, Victor M Orellana-Noia, Craig A Portell, Ashwin Chandar, Kevin A David, Anshu Giri, Brian T Hess, Daniel J Landsburg
BACKGROUND: Salvage immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation is the standard-of-care second-line treatment for patients with relapsed/refractory diffuse large B-cell lymphoma after first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Outcomes after receipt of second-line immunochemotherapy in patients with aggressive B-cell lymphomas who relapse or are refractory to intensive first-line immunochemotherapy regimens (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [R-EPOCH], rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and cytarabine [R-HyperCVAD], rituximab, cyclophosphamide, vincristine, doxorubicin, and high-dose methotrexate alternating with ifosfamide, etoposide, and cytarabine [R-CODOX-M/IVAC]) remain unknown...
January 15, 2020: Cancer